Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

If you are looking for stocks that are well positioned to maintain their recent uptrend, Brainsway (BWAY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

BrainsWay has delivered strong revenue growth, expanding its leasing model and recurring revenue base. BWAY reported 27% annual revenue growth, 75.4% gross margin, and issued 2026 guidance for $66–68M revenue and $12–14M adjusted EBITDA. The leasing model drives high-margin, stable recurring revenue with 93% customer retention and $70M in remaining performance obligations.

BrainsWay's investment is part of its ongoing strategy to partner with leading U.S. mental health providers to increase access to care BrainsWay's investment is part of its ongoing strategy to partner with leading U.S. mental health providers to increase access to care

BrainsWay Ltd. (BWAY) Q4 2025 Earnings Call Transcript

BrainsWay Ltd. (NASDAQ: BWAY) reported fourth-quarter financial results on Wednesday ahead of the market open.

World's only FDA-cleared Deep TMS™ accelerated treatment reduces the acute phase of treatment by 70% World's only FDA-cleared Deep TMS™ accelerated treatment reduces the acute phase of treatment by 70%

BURLINGTON, Mass. and JERUSALEM, Feb. 25, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation technologies, today announced that it will report its fourth quarter and full year 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Wednesday, March 11, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.